MK-677 Increases Growth Hormone and IGF-1 While Improving Body Composition in Older Adults

MK-677 is unique because it's an oral growth hormone secretagogue that actually works—most GH peptides require injection because they're broken down in the gut. Being a ghrelin mimetic, it stimulates your pituitary to release GH in a pulsatile pattern that mimics natural secretion. What makes this study particularly relevant is the population: elderly adults, where the goal isn't supraphysiological GH but restoration of more youthful levels. The improvements in lean mass and bone markers suggest MK-677 may help counter sarcopenia and osteoporosis, two major drivers of frailty in aging. The fact that it maintained efficacy over 12 months without developing tolerance is crucial—many GH interventions lose effectiveness as the body adapts.

MK-677 (Ibutamoren) was developed by Merck as an orally active growth hormone secretagogue, mimicking the action of ghrelin, the 'hunger hormone' that also stimulates GH release. Unlike peptide GHRH analogs, MK-677 is a small molecule that survives gastric digestion, making oral dosing viable. This 1999 study was part of extensive clinical development for age-related frailty and hip fracture recovery. While MK-677 never achieved FDA approval (concerns about edema and glucose elevation in some trials), it completed Phase III development and has been studied in thousands of patients. The compound's ability to sustain elevated GH and IGF-1 for months without desensitization makes it particularly interesting for longevity research. The ghrelin mimetic mechanism also explains the common side effect of increased appetite, which can be a feature or a bug depending on goals.

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on markers of bone turnover in healthy and functionally impaired elderly subjects